Program
PD-L1 Inhibitor ABSK043
Also written as “ABSK043 oral capsule”, “ABSK043 in combination with Osimertinib” and “ABSK043 in combination with Glecirasib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma, Transitional Cell, led by Abbisko Cayman.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Cayman | 55 open or running | phase 2since Oct 1, 2024 | Jun 24, 2021 | Jul 30, 2027phase 1 · NCT04964375 |
Also a collaborator on its studies: AstraZeneca.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 24, 2021First study: phase 1 study in NeoplasmsFirst studyNCT04964375 · 102 enrolled · Australia, China
- Oct 1, 20242 phase 2 studiesNCT06632262, NCT06668103
- Sep 2, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07164170 · 86 planned · China
- Jul 14, 2026Phase 2 study in Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 PositiveNCT07710612 · 72 planned · China
- Nov 6, 2026Primary completion moved from 2022-10-23 to 2027-07-30Date moved laterphase 1 · +57 months · NCT04964375
Ahead
- Jul 30, 2027Primary completion: phase 1 study in NeoplasmsNCT04964375
- Dec 30, 2027Primary completion: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationNCT06668103
- Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07164170
- Nov 30, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellNCT06632262
TargetBeta
“An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07710612Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive · China | 2 | Not yet recruiting | Dec 31, 2029 | 72 |
| NCT07164170Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Dec 30, 2028 | 86 |
| NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation · China | 2 | Recruiting | Dec 30, 2027 | 54 |
| NCT06632262Carcinoma, Transitional Cell · China | 2 | Recruiting | Nov 30, 2029 | 202 |
| NCT04964375Neoplasms · Australia, China | 1 | Active, not recruiting | Jul 30, 2027 | 102 |
How it is read
Names in the registry
- “ABSK043 oral capsule”, 1 entry
- “ABSK043 in combination with Osimertinib”, 1 entry
- “ABSK043 in combination with Glecirasib”, 1 entry
- “ABSK043 in combination with Firmonertinib”, 1 entry
- “ABSK061 + ABSK043”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Neoplasms, 1 study
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.